| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 69.2% | 68.8% | ▼ -0.4% |
| Healthcare Services | 22.2% | 22.6% | ▲ +0.4% |
| Chemicals & Petrochemicals | 4.7% | 4.7% | ● 0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 68.8% | 60.6% | ▼ -8.2% |
| Healthcare Services | 22.6% | 27.0% | ▲ +4.3% |
| Chemicals & Petrochemicals | 4.7% | 5.4% | ▲ +0.7% |
Comparing Apr 2026 → May 2026
| # | Stock | Sector | Weight (May 2026) |
|---|---|---|---|
| 1 | Zydus Lifesciences Limited ₹2.80 Cr |
Pharmaceuticals & Biotechnology | 3.15% |
| 2 | Aster DM Healthcare Limited ₹2.73 Cr |
Healthcare Services | 3.07% |
| 3 | Biocon Limited ₹2.72 Cr |
Pharmaceuticals & Biotechnology | 3.06% |
| # | Stock | Sector | Last Weight (Apr 2026) |
|---|---|---|---|
| 1 | Piramal Pharma Limited ₹3.66 Cr |
Pharmaceuticals & Biotechnology | 4.33% |
| 2 | Alkem Laboratories Limited ₹2.70 Cr |
Pharmaceuticals & Biotechnology | 3.20% |
| 3 | Cipla Limited ₹2.56 Cr |
Pharmaceuticals & Biotechnology | 3.03% |
| 4 | Abbott India Limited ₹2.46 Cr |
Pharmaceuticals & Biotechnology | 2.91% |
| 5 | Concord Biotech Limited ₹2.34 Cr |
Pharmaceuticals & Biotechnology | 2.77% |
| 6 | Vinati Organics Limited ₹1.16 Cr |
Chemicals & Petrochemicals | 1.37% |
| # | Stock | Sector | Apr 2026 | May 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹6.72 Cr |
Pharmaceuticals & Biotechnology | 4.74% | 7.56% | +2.82% |
| 2 | Navin Fluorine International Limited ₹4.79 Cr |
Chemicals & Petrochemicals | 3.32% | 5.38% | +2.06% |
| 3 | Global Health Limited ₹2.65 Cr |
Healthcare Services | 1.98% | 2.97% | +0.99% |
| 4 | Neuland Laboratories Limited ₹4.89 Cr |
Pharmaceuticals & Biotechnology | 4.59% | 5.49% | +0.90% |
| 5 | Gland Pharma Limited ₹3.16 Cr |
Pharmaceuticals & Biotechnology | 2.91% | 3.55% | +0.64% |
| 6 | Acutaas Chemicals Ltd ₹1.97 Cr |
Pharmaceuticals & Biotechnology | 1.93% | 2.22% | +0.29% |
| 7 | Metropolis Healthcare Limited ₹2.63 Cr |
Healthcare Services | 2.67% | 2.95% | +0.28% |
| 8 | Artemis Medicare Services Limited ₹2.56 Cr |
Healthcare Services | 2.70% | 2.87% | +0.17% |
| 9 | Apollo Hospitals Enterprise Limited ₹5.90 Cr |
Healthcare Services | 6.52% | 6.63% | +0.11% |
| 10 | Dr Agarwals Health Care Limited ₹1.92 Cr |
Healthcare Services | 2.08% | 2.15% | +0.07% |
| # | Stock | Sector | Apr 2026 | May 2026 | Change |
|---|---|---|---|---|---|
| 1 | Onesource Specialty Pharma Limited ₹2.74 Cr |
Pharmaceuticals & Biotechnology | 4.56% | 3.08% | -1.48% |
| 2 | Sun Pharmaceutical Industries Limited ₹9.43 Cr |
Pharmaceuticals & Biotechnology | 11.22% | 10.61% | -0.61% |
| 3 | Glenmark Pharmaceuticals Limited ₹2.73 Cr |
Pharmaceuticals & Biotechnology | 3.41% | 3.07% | -0.34% |
| 4 | Fortis Healthcare Limited ₹4.00 Cr |
Healthcare Services | 4.70% | 4.49% | -0.21% |
| 5 | Aurobindo Pharma Limited ₹4.43 Cr |
Pharmaceuticals & Biotechnology | 5.15% | 4.98% | -0.17% |
| 6 | IPCA Laboratories Limited ₹2.53 Cr |
Pharmaceuticals & Biotechnology | 3.01% | 2.85% | -0.16% |
| 7 | Max Healthcare Institute Limited ₹1.62 Cr |
Healthcare Services | 1.97% | 1.82% | -0.15% |
| 8 | Anthem Biosciences Limited ₹1.93 Cr |
Pharmaceuticals & Biotechnology | 2.28% | 2.16% | -0.12% |
23 stocks — May 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹9.43 Cr |
Pharmaceuticals & Biotechnology |
10.61%
|
|
| 2 |
₹6.72 Cr |
Pharmaceuticals & Biotechnology |
7.56%
|
|
| 3 |
₹5.90 Cr |
Healthcare Services |
6.63%
|
|
| 4 |
₹5.79 Cr |
Pharmaceuticals & Biotechnology |
6.51%
|
|
| 5 |
₹4.89 Cr |
Pharmaceuticals & Biotechnology |
5.49%
|
|
| 6 |
₹4.79 Cr |
Chemicals & Petrochemicals |
5.38%
|
|
| 7 |
₹4.43 Cr |
Pharmaceuticals & Biotechnology |
4.98%
|
|
| 8 |
₹4.00 Cr |
Healthcare Services |
4.49%
|
|
| 9 |
₹3.16 Cr |
Pharmaceuticals & Biotechnology |
3.55%
|
|
| 10 |
₹2.80 Cr |
Pharmaceuticals & Biotechnology |
3.15%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.